We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Inozyme Pharma Inc
7 own
15 watching
Current Price
$2.1
$0.35
(20%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
84.83M
52-Week High
7.98
52-Week Low
0.991
Average Volume
0.35M
Dividend Yield
--
P/E Ratio
--
Market Capitalization84.83M52-Week High7.9852-Week Low0.991Average Volume0.35MDividend Yield--P/E Ratio--What does the Inozyme Pharma Inc do?
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company s lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Read More
How much money does Inozyme Pharma Inc make?
News & Events about Inozyme Pharma Inc.
Globe Newswire
18days ago
- Company to share topline data from ongoing Phase 1/2 trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency at virtual event on Thursday, Feb. 16, 2023 - Significant clinical and scientific milestones across ENPP1 Deficiency and ABCC6 Deficiency programs achieved in 2022 - BOSTON, Jan. 09, ...
Globe Newswire
1month ago
- Article in Orphanet Journal of Rare Diseases estimates genetic prevalence of ENPP1 Deficiency at 1 in 64,000 pregnancies, more than tripling prior estimate - - Company estimates addressable patient population with ENPP1 Deficiency at 37,000 worldwide; 2,800 in North America, 4,100 in Europe and ...
Globe Newswire
1month ago
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Axel Bolte, MSc, MBA, the companys co-founder...
Globe Newswire
2 months ago
- Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022 - Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023 - Liquidity and capital resources as of quarter end funds cash flow ...
Globe Newswire
5 months ago
- Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - Secured flexible debt facility for up to $70 million - - ...
Frequently Asked Questions
Frequently Asked Questions
What is Inozyme Pharma Inc share price today?
Can Indians buy Inozyme Pharma Inc shares?
How can I buy Inozyme Pharma Inc shares from India?
Can Fractional shares of Inozyme Pharma Inc be purchased?
What are the documents required to start investing in Inozyme Pharma Inc stocks?
What is today’s traded volume of Inozyme Pharma Inc?
What is today’s market capitalisation of Inozyme Pharma Inc?
What is the 52-Week High and Low Range of Inozyme Pharma Inc?
What percentage is Inozyme Pharma Inc down from its 52-Week High?
What percentage is Inozyme Pharma Inc up from its 52-Week Low?
Current Price
$2.1
$0.35
(20%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.